title: Prevention of pollen rhinitis symptoms: comparison of fluticasone propionate aqueous nasal spray and disodium cromoglycate aqueous nasal spray. A multicenter, double-blind, double-dummy, parallel-group study.
abstract: Fluticasone propionate aqueous spray, a new intranasal corticosteroid preparation, and disodium cromoglycate 2% aqueous nasal spray, an established preventive treatment for seasonal allergic rhinitis, were compared in a double-blind, double-dummy, parallel-group, multicentric study in France. A total of 218 patients with seasonal allergic rhinitis caused by grass pollen (verified by positive skin prick test) were preventively treated before the onset of the grass pollen season with either fluticasone propionate 200 micrograms once daily or disodium cromoglycate 5.2 mg four times daily. Half of these doses was given in each nostril. Treatment started before the onset of the pollen season in most patients (178/218). Diary cards, including symptoms of rhinitis and usage of nasal sprays, were filled in twice daily for 6 weeks. Terfenadine in 60-mg tablets and eye-drops could be used as rescue medications. We treated 110 patients with fluticasone propionate and 108 patients with disodium cromoglycate. Patients treated with fluticasone propionate had significantly more days free of primary efficacy symptoms of sneezing (P < 0.001) and nasal discharge during the day (P = 0.002), as well as free of all the other nasal symptoms (P < 0.01), and significantly lower median scores (P < 0.05) for all nasal symptoms except nasal discharge than patients treated with disodium cromoglycate. There was no difference in eye symptoms or in rescue medication use between the two groups. Compliance with the treatment was assessed.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Clinique des Maladies Respiratoires, Montpellier, France.
authors.forename: J
authors.initials: J
authors.lastname: Bousquet
authors.forename: I
authors.initials: I
authors.lastname: Chanal
authors.forename: M C
authors.initials: MC
authors.lastname: Alquié
authors.forename: D
authors.initials: D
authors.lastname: Charpin
authors.forename: A
authors.initials: A
authors.lastname: Didier
authors.forename: J
authors.initials: J
authors.lastname: Germouty
authors.forename: P
authors.initials: P
authors.lastname: Greillier
authors.forename: M H
authors.initials: MH
authors.lastname: Ickovic
authors.forename: Y
authors.initials: Y
authors.lastname: Maria
authors.forename: F
authors.initials: F
authors.lastname: Montané
mesh_terms: D000281:Administration, Intranasal; D000293:Adolescent; D000328:Adult; D000368:Aged; D000730:Androstadienes / Q000008:administration & dosage* / Q000009:adverse effects; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage* / Q000009:adverse effects; D002648:Child; D004205:Cromolyn Sodium / Q000008:administration & dosage* / Q000009:adverse effects; D004311:Double-Blind Method; D000068298:Fluticasone; D005938:Glucocorticoids; D006801:Humans; D008875:Middle Aged; D010349:Patient Compliance; D006255:Rhinitis, Allergic, Seasonal / Q000517:prevention & control*; D016593:Terfenadine / Q000627:therapeutic use
chemical_list: D000730:Androstadienes; D000893:Anti-Inflammatory Agents; D005938:Glucocorticoids; D016593:Terfenadine; D000068298:Fluticasone; D004205:Cromolyn Sodium